Literature DB >> 12922126

Protective efficacy of a fully recombinant plague vaccine in the guinea pig.

S M Jones1, K F Griffin, I Hodgson, E D Williamson.   

Abstract

A fully recombinant sub-unit vaccine comprising the protein antigens rF1 + rV has been demonstrated to protect immunised guinea pigs against exposure to 10(5) colony-forming units (CFU) of virulent Yersinia pestis. Additionally, IgG purified from rF1 + rV-immunised guinea pig serum, protected the mouse by passive immunisation against challenge with Y. pestis whereas IgG purified from the serum of guinea pigs immunised with a licensed killed whole cell (KWC) vaccine for plague, protected less well. Guinea pigs immunised with the licensed killed whole cell vaccine developed an IgG titre for fraction 1 (F1) but not for V antigen. The differential in protection conferred on the mouse by passive immunisation with guinea pig IgG, was abrogated by the use of IgG purified from guinea pigs immunised with killed whole cell vaccine supplemented with V antigen. These findings indicate that the reduced efficacy of the licensed killed whole cell vaccine formulation previously observed in the mouse can be attributed to lack of the V antigen. Cross-protection of the mouse with guinea pig IgG suggests that the recognition of neutralising epitopes in the F1 and V proteins is conserved between these two species.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922126     DOI: 10.1016/s0264-410x(03)00379-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

Authors:  Kristin L DeBord; Deborah M Anderson; Melanie M Marketon; Katie A Overheim; R William DePaolo; Nancy A Ciletti; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

2.  Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system.

Authors:  Luca Santi; Anatoli Giritch; Chad J Roy; Sylvestre Marillonnet; Victor Klimyuk; Yuri Gleba; Robert Webb; Charles J Arntzen; Hugh S Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

Review 3.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

4.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

5.  Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Authors:  E D Williamson; H C Flick-Smith; C Lebutt; C A Rowland; S M Jones; E L Waters; R J Gwyther; J Miller; P J Packer; M Irving
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Authors:  Shixia Wang; Innocent Mboudjeka; Jon D Goguen; Shan Lu
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

7.  An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Authors:  Sue Stacy; Amanda Pasquali; Valerie L Sexton; Angelene M Cantwell; Ellen Kraig; Peter H Dube
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 8.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

9.  Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein.

Authors:  Sara Schesser Bartra; Katie L Styer; Deanna M O'Bryant; Matthew L Nilles; B Joseph Hinnebusch; Alejandro Aballay; Gregory V Plano
Journal:  Infect Immun       Date:  2007-11-19       Impact factor: 3.441

10.  Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Authors:  Joanne Huang; Ajit J D'Souza; Jason B Alarcon; John A Mikszta; Brandi M Ford; Matthew S Ferriter; Michelle Evans; Todd Stewart; Kei Amemiya; Robert G Ulrich; Vincent J Sullivan
Journal:  Clin Vaccine Immunol       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.